Rekombinanter CSF2 (Otilimab Biosimilar) Antikörper
Kurzübersicht für Rekombinanter CSF2 (Otilimab Biosimilar) Antikörper (ABIN7676054)
Target
Antikörpertyp
Reaktivität
Wirt
Klonalität
Applikation
-
-
Expressionssystem
- CHO Cells
-
Verwendungszweck
- Anti-CSF2 / GM-CSF Reference Antibody (otilimab)
-
Sequenz
- QVQLVESGGG LVQPGGSLRL SCAASGFTFS SYWMNWVRQA PGKGLEWVSG IENKYAGGAT YYAASVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR GFGTDFWGQG TLVTVSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC NVNHKPSNTK VDKRVEPKSC DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK,DIELTQPPSV SVAPGQTARI SCSGDSIGKK YAYWYQQKPG QAPVLVIYKK RPSGIPERFS GSNSGNTATL TISGTQAEDE ADYYCSAWGD KGMVFGGGTK LTVLGQPKAA PSVTLFPPSS EELQANKATL VCLISDFYPG AVTVAWKADS SPVKAGVETT TPSKQSNNKY AASSYLSLTP EQWKSHRSYS CQVTHEGSTV EKTVAPTECS
-
Produktmerkmale
- Anti-CSF2 / GM-CSF Reference Antibody (otilimab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hulambda. It has a predicted MW of 145.5 kDa.
-
Reinheit
- >95 %
-
Isotyp
- IgG1
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Kommentare
-
Therapeutic Agents by Target and Mechanism: GM-CSF inhibitors
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Konzentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Lagerung
- 4 °C,-80 °C
-
Informationen zur Lagerung
- +4°C,-80°C
-
-
- CSF2 (Otilimab Biosimilar)
-
Substanzklasse
- Biosimilar
-
Molekulargewicht
- 145.5 kDa
-
UniProt
- P04141
Target
-